PMCID	SENTENCE_NUMBER	SENTENCE	SENTENCE_INDICES	ONTOLOGY_CONCEPT_IDS_LIST
17020410	0	['Rescue of Progeria in Trichothiodystrophy by Homozygous Lethal Xpd Alleles\n\nAbstract\n\nAlthough compound heterozygosity, or the presence of two different mutant alleles of the same gene, is common in human recessive disease, its potential to impact disease outcome has not been well documented.']	(0, 293)	['GO_EXT:fatality_or_lethality', 'NCBITaxon:9606', 'PR_EXT:000007164', 'SO_EXT:sequence_rescue_process', 'SO_EXT:0001023', 'SO_EXT:sequence_altered_entity_or_alteration_process', 'SO_EXT:0001023', 'SO_EXT:0000704']
17020410	1	['This is most likely because of the inherent difficulty in distinguishing specific biallelic effects from differences in environment or genetic background.']	(294, 448)	['SO_EXT:0001023', 'SO_EXT:0000704']
17020410	2	['We addressed the potential of different recessive alleles to contribute to the enigmatic pleiotropy associated with XPD recessive disorders in compound heterozygous mouse models.']	(449, 627)	['NCBITaxon:10088', 'PR_EXT:000007164', 'SO_EXT:0001023']
17020410	3	['Alterations in this essential helicase, with functions in both DNA repair and basal transcription, result in diverse pathologies ranging from elevated UV sensitivity and cancer predisposition to accelerated segmental progeria.']	(628, 854)	['CHEBI_SO_EXT:DNA', 'GO:0006281', 'GO:0006281', 'GO_EXT:transcription', 'GO_EXT:0004386', 'SO_EXT:sequence_alteration_entity_or_process', 'CHEBI_SO_EXT:DNA']
17020410	4	['We report a variety of biallelic effects on organismal phenotype attributable to combinations of recessive Xpd alleles, including the following: (i) the ability of homozygous lethal Xpd alleles to ameliorate a variety of disease symptoms when their essential basal transcription function is supplied by a different disease-causing allele, (ii) differential developmental and tissue-specific functions of distinct Xpd allele products, and (iii) interallelic complementation, a phenomenon rarely reported at clinically relevant loci in mammals.']	(855, 1397)	['GO_EXT:fatality_or_lethality', 'GO_EXT:transcription', 'NCBITaxon:1', 'NCBITaxon:40674', 'PR_EXT:000007164', 'PR_EXT:000007164', 'PR_EXT:000007164', 'SO_EXT:0001023', 'SO_EXT:0001023', 'SO_EXT:0001023', 'SO_EXT:0001023', 'SO_EXT:0001023', 'SO_EXT:0001023', 'UBERON:0000479']
17020410	5	['Our data suggest a re-evaluation of the contribution of “null” alleles to XPD disorders and highlight the potential of combinations of recessive alleles to affect both normal and pathological phenotypic plasticity in mammals.']	(1398, 1623)	['NCBITaxon:40674', 'PR_EXT:000007164', 'SO_EXT:sequence_nullness', 'SO_EXT:0001023', 'SO_EXT:0001023']
17020410	6	['Introduction\n\nInterallelic complementation is defined as the ability of two differentially mutated alleles to function better together than either can on its own.']	(1625, 1787)	['SO_EXT:0001023', 'SO_EXT:sequence_alteration_process', 'SO_EXT:0001023']
17020410	7	['Despite its near universality in lower organisms [1], its potential to contribute to clinical heterogeneity in human disease is seldom considered.']	(1788, 1934)	['NCBITaxon:1', 'NCBITaxon:9606']
17020410	8	['Evidence of interallelic complementation at clinically relevant loci is limited to biochemical and cell-based studies of a handful of metabolic disorders with defects in enzymes including propinyl-CoA carboxylase [2], argininosuccinate lyase [3], galactose-1-phosphate uridylyltransferase [4], and methylmalonyl CoA mutase [5].']	(1935, 2262)	['CHEBI_EXT:biochemical', 'CHEBI_GO_SO_EXT:enzyme', 'CHEBI:15539', 'CHEBI:15539', 'CHEBI:15539', 'CHEBI:57472', 'CHEBI:53025', 'CHEBI:53025', 'CHEBI:53025', 'CHEBI:53025', 'CHEBI:53025', 'CHEBI:16625', 'CHEBI:16625', 'CL_GO_EXT:cell', 'GO:0008152', 'CL_GO_EXT:cell', 'CHEBI_GO_SO_EXT:enzyme', 'GO_EXT:0004658', 'GO_EXT:0004658', 'GO_EXT:0004658', 'GO_EXT:0004658', 'GO_PR_EXT:argininosuccinate_lyase', 'GO_PR_EXT:argininosuccinate_lyase', 'GO_PR_EXT:galactose_1_phosphate_uridylyltransferase', 'GO_PR_EXT:galactose_1_phosphate_uridylyltransferase', 'GO_PR_EXT:galactose_1_phosphate_uridylyltransferase', 'GO_PR_EXT:galactose_1_phosphate_uridylyltransferase', 'GO_PR_EXT:galactose_1_phosphate_uridylyltransferase', 'GO_PR_EXT:galactose_1_phosphate_uridylyltransferase', 'GO_PR_EXT:methylmalonyl_CoA_mutase', 'GO_PR_EXT:methylmalonyl_CoA_mutase', 'GO_PR_EXT:methylmalonyl_CoA_mutase', 'GO_PR_EXT:argininosuccinate_lyase', 'GO_PR_EXT:argininosuccinate_lyase', 'GO_PR_EXT:galactose_1_phosphate_uridylyltransferase', 'GO_PR_EXT:galactose_1_phosphate_uridylyltransferase', 'GO_PR_EXT:galactose_1_phosphate_uridylyltransferase', 'GO_PR_EXT:galactose_1_phosphate_uridylyltransferase', 'GO_PR_EXT:galactose_1_phosphate_uridylyltransferase', 'GO_PR_EXT:galactose_1_phosphate_uridylyltransferase', 'GO_PR_EXT:methylmalonyl_CoA_mutase', 'GO_PR_EXT:methylmalonyl_CoA_mutase', 'GO_PR_EXT:methylmalonyl_CoA_mutase', 'SO_EXT:0001023', 'CHEBI_GO_SO_EXT:enzyme']
17020410	9	['Compound heterozygotes are individuals carrying two different mutant alleles of the same gene.']	(2264, 2358)	['NCBITaxon:1', 'SO_EXT:sequence_altered_entity_or_alteration_process', 'SO_EXT:0001023', 'SO_EXT:0000704']
17020410	10	['In the absence of a dominant (wild-type [wt]) allele, genetic interactions between recessive alleles (referred to here as “biallelic” effects) could result in different phenotypic outcomes including interallelic complementation.']	(2359, 2587)	['SO_EXT:wild_type_entity_or_quality', 'SO_EXT:wild_type_entity_or_quality', 'SO_EXT:wild_type_entity_or_quality', 'SO_EXT:wild_type_entity_or_quality', 'SO_EXT:0001023', 'SO_EXT:0000704', 'SO_EXT:0001023', 'SO_EXT:0001023', 'SO_EXT:0001023']
17020410	11	['Although amelioration of disease symptoms by interallelic complementation would create an ascertainment bias in the clinic, the lack of evidence concerning interallelic complementation or other biallelic effects in human disease is likely caused by the difficulty in distinguishing such effects from environment and genetic background.']	(2588, 2923)	['NCBITaxon:9606', 'SO_EXT:0001023', 'SO_EXT:0001023', 'SO_EXT:0001023', 'SO_EXT:0000704']
17020410	12	['XPD encodes one of the two helicase components of basal transcription/DNA repair factor IIH (TFIIH), a ten-subunit, multifunctional complex that is essential for multiple processes, including basal transcription initiation and DNA damage repair via the nucleotide excision repair (NER) pathway [6,7].']	(2925, 3225)	['CHEBI_SO_EXT:DNA', 'CHEBI_SO_EXT:DNA', 'CHEBI_SO_EXT:nucleotide', 'GO_EXT:transcription', 'GO:0006281', 'GO:0006281', 'GO_EXT:transcription', 'GO:0006281', 'GO:0006281', 'GO:0006281', 'GO:0006289', 'GO:0006289', 'GO:0006289', 'GO:0006289', 'GO:0005675', 'GO:0005675', 'GO:0005675', 'GO:0005675', 'GO:0005675', 'GO:0005675', 'GO:0005675', 'GO:0005675', 'GO:0032991', 'GO_EXT:0004386', 'GO_EXT:transcription_factor', 'GO_EXT:transcription_factor', 'PR_EXT:000007164', 'SO_EXT:sequence_coding_function', 'CHEBI_SO_EXT:DNA', 'CHEBI_SO_EXT:DNA', 'CHEBI_SO_EXT:nucleotide', 'SO_EXT:sequence_deletion_process']
17020410	13	['Alterations in XPD resulting in defective TFIIH function are associated with UV-sensitive, multisystem disorders including xeroderma pigmentosum (XP), XP combined with Cockayne syndrome (CS), and trichothiodystrophy (TTD) [8–10].']	(3226, 3455)	['GO:0005675', 'PR_EXT:000007164', 'SO_EXT:sequence_alteration_entity_or_process', 'UBERON:0000467']
17020410	14	['XP is marked by sun-induced pigmentation anomalies and a greater than 1,000-fold elevation in skin cancer risk.']	(3456, 3567)	['GO_PATO_EXT:biological_pigmentation_process_or_quality', 'UBERON_EXT:zone_of_skin_or_skin_of_body']
17020410	15	['Severe cases can also present with growth retardation and primary neurodegeneration [11].']	(3568, 3657)	['GO_EXT:biological_growth_entity_or_process']
17020410	16	['CS and TTD, on the other hand, are segmental progeroid disorders characterised by progressive post-natal growth failure and primary demyelination resulting in severe neurodysfunction, but without a clear cancer predisposition [12–15].']	(3658, 3892)	['GO:0007567', 'GO_EXT:biological_growth_entity_or_process', 'GO_EXT:myelin_assembly_or_myelination']
17020410	17	['Patients with TTD additionally display hallmark sulphur-deficient brittle hair and nails and scaling skin [13], resulting from a basal transcription defect in specific cell types [16,17].']	(3893, 4080)	['CHEBI_EXT:sulfur', 'CL_GO_EXT:cell', 'GO_EXT:transcription', 'CL_GO_EXT:cell', 'UBERON:0001037', 'UBERON:0001705', 'UBERON_EXT:zone_of_skin_or_skin_of_body']
17020410	18	['A related disorder with the cancer predisposition of XP combined with the neurodevelopmental complications of CS (XPCS), although rare, has also been described [18].']	(4081, 4246)	['GO:0007399']
17020410	19	['Many XPD mutations are associated with an exclusive disease phenotype (e.g., XPDR722W with TTD and XPDR683W with XP) and are thus viewed as causative of the corresponding syndromes.']	(4248, 4429)	['PR_EXT:000007164', 'PR_EXT:000007164', 'PR_EXT:000007164', 'SO_EXT:sequence_alteration_entity_or_process']
17020410	20	['Alleles not associated exclusively with one disorder are considered “likely null” alleles [19,20].']	(4430, 4528)	['SO_EXT:0001023', 'SO_EXT:sequence_nullness', 'SO_EXT:0001023']
17020410	21	['Some of these alleles fail to support viability in a haploid Schizosaccharomyces pombe yeast strain with a null mutation in the XPD homologue rad15 and are thus considered devoid of significant biological activity [19].']	(4529, 4748)	['CHEBI_GO_EXT:biological_process_or_quality_or_role', 'CHEBI_GO_EXT:biological_process_or_quality_or_role', 'NCBITaxon:4896', 'NCBITaxon:4896', 'NCBITaxon:4896', 'PR_EXT:000007164', 'PR_EXT:P26659', 'SO_EXT:0001023', 'SO_EXT:sequence_nullness', 'SO_EXT:sequence_alteration_entity_or_process', 'SO_EXT:0000853']
17020410	22	['This classification of alleles as either causative or null currently defines what we refer to as a “monoallelic” paradigm of XPD disease.']	(4749, 4886)	['PR_EXT:000007164', 'SO_EXT:0001023', 'SO_EXT:sequence_nullness', 'SO_EXT:0001023']
17020410	23	['However, the identification in recent years of XP complementation group D patients with atypical disease presentation, including symptoms of both XP and TTD [8], casts doubt on the ability of such a monoallelic paradigm to explain clinical heterogeneity in compound heterozygotes.']	(4887, 5167)	['SO_EXT:0001023']
17020410	24	['Previously, we generated a TTD mouse model (XPDR722W) that phenocopies the human syndrome [15,21].']	(5169, 5267)	['NCBITaxon:10088', 'NCBITaxon:9606', 'PR_EXT:000007164']
17020410	25	['Here we report the generation of additional mutant Xpd alleles that fail to support viability on their own but nevertheless ameliorate TTD-associated premature segmental ageing, cutaneous features, cellular DNA repair capacity, and UV survival when present in a compound heterozygote state.']	(5268, 5558)	['CHEBI_SO_EXT:DNA', 'CL_GO_EXT:cell', 'GO:0007568', 'GO:0006281', 'GO:0006281', 'CL_GO_EXT:cell', 'PR_EXT:000007164', 'SO_EXT:sequence_altered_entity_or_alteration_process', 'SO_EXT:0001023', 'CHEBI_SO_EXT:DNA', 'UBERON_EXT:zone_of_skin_or_skin_of_body']
17020410	26	['Results\n\nGeneration of Xpd Compound Heterozygotes\n\nWe generated an Xpd knock-in allele with a point mutation encoding a single amino acid change (XPDG602D) found in the XPCS patient XPCS2 (Figure 1A–1C).']	(5560, 5763)	['CHEBI_SO_EXT:amino_acid', 'CHEBI_SO_EXT:amino_acid', 'PR_EXT:000007164', 'PR_EXT:000007164', 'PR_EXT:000007164', 'SO_EXT:0001023', 'SO_EXT:point_mutation_entity_or_process', 'SO_EXT:point_mutation_entity_or_process', 'SO_EXT:sequence_coding_function', 'CHEBI_SO_EXT:amino_acid', 'CHEBI_SO_EXT:amino_acid', 'SO_EXT:sequence_alteration_entity_or_process']
17020410	27	['mRNA expression from the targeted allele could be detected in embryonic stem cells by RT-PCR (Figure 1D), although expression was reduced approximately 5-fold relative to wt mRNA transcript levels as determined by Northern blotting of RNA from the testis of heterozygous animals (Figure 1E).']	(5764, 6055)	['CHEBI_SO_EXT:mRNA', 'CHEBI_SO_EXT:mRNA', 'CHEBI_SO_EXT:RNA', 'CL:0002322', 'CL:0002322', 'CL:0002322', 'GO:0010467', 'GO_EXT:reverse_transcription_or_reverse_transcriptase', 'GO:0010467', 'CL_GO_EXT:cell', 'GO_EXT:reverse_transcription_or_reverse_transcriptase', 'NCBITaxon:33208', 'CHEBI_SO_EXT:mRNA', 'SO_EXT:0001023', 'SO_EXT:wild_type_entity_or_quality', 'CHEBI_SO_EXT:mRNA', 'CHEBI_SO_EXT:RNA', 'UBERON:0000922', 'UBERON:0000473']
17020410	28	['Because patient XPCS2 was a hemizygote with mutant XPD protein (XPDG602D) expressed from a single allele, the corresponding mutation was expected to be viable in the homozygous state.']	(6056, 6239)	['CHEBI_PR_EXT:protein', 'GO:0010467', 'PR_EXT:000007164', 'CHEBI_PR_EXT:protein', 'PR_EXT:000007164', 'SO_EXT:sequence_altered_entity_or_alteration_process', 'SO_EXT:0001023', 'SO_EXT:sequence_alteration_entity_or_process']
17020410	29	['However, homozygous mutant mice were not observed, neither amongst live births nor embryonic day 13.5 (E13.5) or E3.5 embryos (Table 1).']	(6240, 6376)	['NCBITaxon:10088', 'SO_EXT:sequence_altered_entity_or_alteration_process', 'UBERON:0000922', 'UBERON:0000922']
17020410	30	['The corresponding hypomorphic, mutant allele was thus designated as homozygous lethal (†XPCS).']	(6377, 6471)	['GO_EXT:fatality_or_lethality', 'SO_EXT:sequence_altered_entity_or_alteration_process', 'SO_EXT:0001023']
17020410	31	['Homozygous lethality of the XPCS allele is likely due to reduced levels of expression of this essential protein as a result of gene targeting (Figure 1A) rather than to the mutation itself.']	(6472, 6661)	['CHEBI_PR_EXT:protein', 'GO_EXT:fatality_or_lethality', 'GO:0010467', 'CHEBI_PR_EXT:protein', 'SO_EXT:0001023', 'SO_EXT:0000704', 'SO_EXT:sequence_alteration_entity_or_process']
17020410	32	['Xpd ablation (XpdKO/KO) is similarly incompatible with life beyond the earliest stages of embryogenesis [22].']	(6662, 6771)	['GO:0009790', 'PR_EXT:000007164', 'PR_EXT:000007164', 'UBERON:0000104']
17020410	33	['Consistent with this interpretation, a different targeted Xpd mutation encoding XPDR683W, which is associated with XP in the homozygous state in humans, was similarly underexpressed and lethal in the homozygous state (designated as †XP allele) (Figure 1A–1C; Table 1; unpublished data).']	(6772, 7058)	['GO:0010467', 'GO_EXT:fatality_or_lethality', 'NCBITaxon:9606', 'PR_EXT:000007164', 'PR_EXT:000007164', 'SO_EXT:sequence_alteration_entity_or_process', 'SO_EXT:sequence_coding_function', 'SO_EXT:0001023']
17020410	34	['Also, a different targeting approach leading to the use of the native 3′UTR and removal of the neo gene resulted in normalisation of XpdXPCS mRNA levels and viable homozygous XpdXPCS/XPCS (XPDG602D/G602D) animals [23].']	(7059, 7277)	['CHEBI_GO_EXT:neomycin_or_neomycin_phosphotransferase', 'CHEBI_SO_EXT:mRNA', 'CHEBI_GO_EXT:neomycin_or_neomycin_phosphotransferase', 'NCBITaxon:33208', 'PR_EXT:000007164', 'PR_EXT:000007164', 'PR_EXT:000007164', 'SO_EXT:0000205', 'SO_EXT:0000205', 'SO_EXT:0000205', 'SO_EXT:0000704', 'CHEBI_SO_EXT:mRNA']
17020410	35	['Figure 1\n\nTargeting of the Mouse Xpd Gene\n\n(A) Schematic representation of the genomic structure and partial restriction map of the wt and targeted mouse Xpd loci.']	(7279, 7442)	['NCBITaxon:10088', 'NCBITaxon:10088', 'PR_EXT:000007164', 'PR_EXT:000007164', 'SO_EXT:0000704', 'SO_EXT:0001026', 'SO_EXT:0001250', 'SO_EXT:0001250', 'SO_EXT:wild_type_entity_or_quality']
17020410	36	['For the wt Xpd allele, shaded boxes represent coding regions of exons 12 and 19–23; the 3′UTR is represented by an open box.']	(7443, 7567)	['PR_EXT:000007164', 'SO_EXT:wild_type_entity_or_quality', 'SO_EXT:0001023', 'SO_EXT:0001215', 'SO_EXT:0001215', 'SO_EXT:0001215', 'SO_EXT:0001215', 'SO_EXT:0000205', 'SO_EXT:0000205', 'SO_EXT:0000205']
17020410	37	['TGA indicates the translational stop codon; PolyA indicates the polyadenylation signal.']	(7568, 7655)	['GO:0006415', 'GO:0006415', 'GO:0043631', 'SO_EXT:0000319', 'SO_EXT:0000319', 'SO_EXT:0000319', 'SO_EXT:0000551', 'SO_EXT:0000551', 'SO_EXT:0000551']
17020410	38	['For the XpdTTD targeted allele, the 194–base pair (bp) human XPD cDNA fragment fused to exon 22 is indicated as a striped box including the TTD (R722W) mutation indicated by a vertical arrow.']	(7656, 7847)	['CHEBI_SO_EXT:base', 'NCBITaxon:9606', 'PR_EXT:000007164', 'PR_EXT:000007164', 'SO_EXT:0001023', 'SO_EXT:0000028', 'SO_EXT:0000028', 'SO_EXT:0000028', 'SO_EXT:cDNA', 'SO_EXT:sequence_fusion_process', 'SO_EXT:0000147', 'SO_EXT:sequence_alteration_entity_or_process']
17020410	39	['Chicken β-globin exons 2 and 3 including the 3′UTR are indicated as black boxes with corresponding Roman numerals followed by the β-globin polyadenylation signal (PolyA*).']	(7848, 8019)	['CHEBI:5386', 'CHEBI:5386', 'GO:0043631', 'NCBITaxon:9031', 'PR_EXT:000008457', 'PR_EXT:000008457', 'PR_EXT:000008457', 'PR_EXT:000008457', 'PR_EXT:000008457', 'PR_EXT:000008457', 'SO_EXT:0000147', 'SO_EXT:0000205', 'SO_EXT:0000205', 'SO_EXT:0000205', 'SO_EXT:0000551', 'SO_EXT:0000551', 'SO_EXT:0000551', 'SO_EXT:0000551']
17020410	40	['For the Xpd†XP and Xpd†XPCS targeted alleles, vertical arrows indicate XPCS (G602D-encoding) and XP (R683W-encoding) mutations in exons 19 and 22, respectively.']	(8020, 8180)	['PR_EXT:000007164', 'PR_EXT:000007164', 'SO_EXT:0001023', 'SO_EXT:sequence_coding_function', 'SO_EXT:sequence_coding_function', 'SO_EXT:sequence_alteration_entity_or_process', 'SO_EXT:0000147']
17020410	41	['The unique 3′ probe located outside the targeting construct is marked by a thick black line.']	(8181, 8273)	['CHEBI_SO_EXT:molecular_probe', 'CHEBI_SO_EXT:molecular_probe', 'SO_EXT:engineered_biological_sequence']
17020410	42	['Restriction sites: B, BamHI; C, ClaI; E, EcoRI; H, HindIII; Hp, HpaI; Sf, SfiI.']	(8274, 8353)	['PR_EXT:P23940', 'PR_EXT:P23940', 'PR_EXT:P43870', 'PR_EXT:P43870', 'SO_EXT:0000061', 'SO_EXT:0000061']
17020410	43	['(B) Southern blot analysis of EcoRI-digested genomic DNA from wt, Xpd†XPCS/wt, and Xpd†XP/wt recombinant embryonic stem cell clones hybridised with the 3′ probe depicted in (A).']	(8355, 8532)	['CHEBI_SO_EXT:DNA', 'CHEBI_SO_EXT:molecular_probe', 'CL:0002322', 'CL:0002322', 'CL:0002322', 'GO_SO_EXT:sequence_rearrangement_process', 'CL_GO_EXT:cell', 'GO:0097617', 'PR_EXT:000007164', 'PR_EXT:000007164', 'SO_EXT:genomic_DNA', 'SO_EXT:genomic_DNA', 'SO_EXT:wild_type_entity_or_quality', 'SO_EXT:wild_type_entity_or_quality', 'SO_EXT:wild_type_entity_or_quality', 'GO_SO_EXT:sequence_rearrangement_process', 'SO_EXT:sequence_cloned_entity', 'CHEBI_SO_EXT:molecular_probe', 'UBERON:0000922']
17020410	44	['The wt allele yields a 6.5-kilobase (kb) fragment, whereas both targeted Xpd†XP and Xpd†XPCS alleles yield a 5.1-kb fragment.']	(8533, 8658)	['CHEBI_SO_EXT:base', 'CHEBI_SO_EXT:base', 'CHEBI_SO_EXT:base', 'PR_EXT:000007164', 'PR_EXT:000007164', 'SO_EXT:wild_type_entity_or_quality', 'SO_EXT:0001023', 'CHEBI_SO_EXT:base', 'CHEBI_SO_EXT:base', 'SO_EXT:0001023', 'CHEBI_SO_EXT:base']
17020410	45	['(C) Genotyping of wt and targeted alleles by PCR using primers F2, R1, and mR as indicated in (A) yields fragments of 399 bp and 468 bp, respectively.']	(8660, 8810)	['SO_EXT:wild_type_entity_or_quality', 'SO_EXT:0001023', 'SO_EXT:0000112', 'SO_EXT:0000028', 'SO_EXT:0000028']
17020410	46	['(D) RT-PCR detection of mRNA expression originating from the targeted †XP and †XPCS alleles in embryonic stem cell clones using primers F1 (hybridising outside the targeting construct) and mR as indicated in (A) results in a 1,416-bp fragment.']	(8812, 9055)	['CHEBI_SO_EXT:mRNA', 'CL:0002322', 'CL:0002322', 'CL:0002322', 'GO_EXT:reverse_transcription_or_reverse_transcriptase', 'GO:0010467', 'CL_GO_EXT:cell', 'GO_EXT:reverse_transcription_or_reverse_transcriptase', 'GO:0097617', 'CHEBI_SO_EXT:mRNA', 'SO_EXT:0001023', 'SO_EXT:sequence_cloned_entity', 'SO_EXT:0000112', 'SO_EXT:engineered_biological_sequence', 'SO_EXT:0000028', 'UBERON:0000922']
17020410	47	['(E) Northern blot analysis of total RNA isolated from testis of homozygous wt and XpdTTD/TTD, heterozygous Xpd†XPCS/wt and XpdTTD/wt, and compound heterozygous Xpd†XPCS/TTD mice as indicated.']	(9057, 9248)	['CHEBI_SO_EXT:RNA', 'NCBITaxon:10088', 'PR_EXT:000007164', 'PR_EXT:000007164', 'PR_EXT:000007164', 'CHEBI_SO_EXT:RNA', 'SO_EXT:wild_type_entity_or_quality', 'SO_EXT:wild_type_entity_or_quality', 'SO_EXT:wild_type_entity_or_quality', 'UBERON:0000473']
17020410	48	['Hybridisation with a 1.4-kb mouse Xpd cDNA probe detects mRNAs of 4, 3.3, and 2.7 kb from wt, Xpd†XPCS, and XpdTTD alleles, respectively.']	(9249, 9386)	['CHEBI_SO_EXT:base', 'CHEBI_SO_EXT:molecular_probe', 'CHEBI_SO_EXT:mRNA', 'CHEBI_SO_EXT:base', 'GO:0097617', 'NCBITaxon:10088', 'PR_EXT:000007164', 'PR_EXT:000007164', 'PR_EXT:000007164', 'CHEBI_SO_EXT:base', 'SO_EXT:cDNA', 'CHEBI_SO_EXT:molecular_probe', 'CHEBI_SO_EXT:mRNA', 'CHEBI_SO_EXT:base', 'SO_EXT:wild_type_entity_or_quality', 'SO_EXT:0001023']
17020410	49	['An ethidium bromide (EtBr)–stained gel showing the amount of total RNA loaded is shown below.']	(9387, 9480)	['CHEBI:4883', 'CHEBI:4883', 'CHEBI:4883', 'CHEBI_SO_EXT:RNA', 'CHEBI_SO_EXT:RNA']
17020410	50	['Table 1\n\nFrequency of Xpd†XP/†XP, Xpd†XPCS/†XPCS, and Compound Heterozygous Xpd†XP/†XPCS Embryos and Offspring\n\n“Null” Allele Can Alleviate Developmental Delay, Skin, and Hair Features of TTD\n\nTo test the potential of a homozygous lethal “null” allele to nevertheless contribute to organismal phenotype, we combined an Xpd†XPCS allele with a viable XpdTTD allele by crossing the corresponding heterozygous animals.']	(9482, 9896)	['GO_EXT:fatality_or_lethality', 'NCBITaxon:1', 'NCBITaxon:33208', 'PR_EXT:000007164', 'PR_EXT:000007164', 'PR_EXT:000007164', 'PR_EXT:000007164', 'PR_EXT:000007164', 'SO_EXT:sequence_nullness', 'SO_EXT:0001023', 'SO_EXT:sequence_nullness', 'SO_EXT:0001023', 'SO_EXT:0001023', 'SO_EXT:0001023', 'UBERON:0000922', 'UBERON_EXT:zone_of_skin_or_skin_of_body', 'UBERON:0001037']
17020410	51	['Similar to hemizygous TTD mice carrying one true Xpd knockout allele (XpdTTD/KO), compound heterozygous XpdTTD/†XPCS mice were born at the expected Mendelian frequencies.']	(9897, 10067)	['GO:0007567', 'NCBITaxon:10088', 'NCBITaxon:10088', 'PR_EXT:000007164', 'PR_EXT:000007164', 'PR_EXT:000007164', 'SO_EXT:0001023']
17020410	52	['Expression from the Xpd†XPCS allele was also reduced in the testis of compound heterozygous animals, whereas expression from the XpdTTD allele was increased relative to wt by ~5-fold (Figure 1E).']	(10068, 10263)	['GO:0010467', 'GO:0010467', 'NCBITaxon:33208', 'PR_EXT:000007164', 'PR_EXT:000007164', 'SO_EXT:0001023', 'SO_EXT:0001023', 'SO_EXT:wild_type_entity_or_quality', 'UBERON:0000473']
17020410	53	['Because of a lack of available antibodies and the inability to distinguish amongst various mutant forms of XPD differing only by single amino acid substitutions, we were unable to ascertain the relative amount of XPD protein from the different alleles.']	(10264, 10516)	['CHEBI_SO_EXT:amino_acid', 'CHEBI_SO_EXT:amino_acid', 'CHEBI_PR_EXT:protein', 'GO:0042571', 'PR_EXT:000007164', 'PR_EXT:000007164', 'CHEBI_PR_EXT:protein', 'SO_EXT:sequence_altered_entity_or_alteration_process', 'CHEBI_SO_EXT:amino_acid', 'CHEBI_SO_EXT:amino_acid', 'SO_EXT:sequence_substitution_entity_or_process', 'SO_EXT:0001023']
17020410	54	['Despite reduced levels of mRNA expression, the homozygous lethal Xpd†XPCS allele ameliorated multiple XpdTTD-associated disease symptoms in compound heterozygous XpdTTD/†XPCS animals including the hallmark brittle hair and cutaneous features fully penetrant in homo- and hemizygous TTD mice (Figure 2A–2C).']	(10518, 10824)	['CHEBI_SO_EXT:mRNA', 'GO:0010467', 'GO_EXT:fatality_or_lethality', 'NCBITaxon:33208', 'NCBITaxon:10088', 'PR_EXT:000007164', 'PR_EXT:000007164', 'PR_EXT:000007164', 'CHEBI_SO_EXT:mRNA', 'SO_EXT:0001023', 'UBERON:0001037', 'UBERON_EXT:zone_of_skin_or_skin_of_body']
17020410	55	['In marked contrast to XpdTTD/TTD (and XpdTTD/KO) mice, which display complete hair loss in the first hair cycle and partial hair loss in subsequent cycles throughout their lives [21], compound heterozygous XpdTTD/†XPCS mice displayed some hair loss only during the first hair cycle and only locally at the back (Figure 2A).']	(10825, 11148)	['GO:0042633', 'GO:0042633', 'GO:0042633', 'GO:0042633', 'NCBITaxon:10088', 'NCBITaxon:10088', 'PR_EXT:000007164', 'PR_EXT:000007164', 'PR_EXT:000007164', 'UBERON:0001037', 'UBERON:0001037', 'UBERON:0001037', 'UBERON:0000104', 'UBERON:0001037', 'UBERON:0001037', 'UBERON:0001137']
17020410	56	['Scanning electron microscope analysis of XpdTTD/†XPCS hair revealed an almost normal appearance, with TTD-like features such as broken hairs found only at very low frequency (unpublished data).']	(11149, 11342)	['CHEBI:10545', 'PR_EXT:000007164', 'UBERON:0001037', 'UBERON:0001037']
17020410	57	['Amino acid analysis confirmed that cysteine levels in the hair of the XpdTTD/†XPCS mice were significantly higher than in XpdTTD/TTD animals, but remained below the wt level (Figure 2C).']	(11343, 11529)	['CHEBI_SO_EXT:amino_acid', 'CHEBI_SO_EXT:amino_acid', 'CHEBI_SO_EXT:cysteine', 'NCBITaxon:10088', 'NCBITaxon:33208', 'PR_EXT:000007164', 'PR_EXT:000007164', 'CHEBI_SO_EXT:amino_acid', 'CHEBI_SO_EXT:amino_acid', 'CHEBI_SO_EXT:cysteine', 'SO_EXT:wild_type_entity_or_quality', 'UBERON:0001037']
17020410	58	['TTD hemizygotes (XpdTTD/KO) do not display significant differences in cutaneous features and longevity relative to homozygous XpdTTD/TTD mice [21].']	(11530, 11677)	['NCBITaxon:10088', 'PR_EXT:000007164', 'PR_EXT:000007164', 'UBERON_EXT:zone_of_skin_or_skin_of_body']
17020410	59	['Figure 2\n\nPartial Rescue of TTD Cutaneous, Blood, and Developmental Phenotypes in Compound Heterozygous XpdTTD/†XPCS Mice\n\n(A) Photographs of 5-mo-old homozygous XpdTTD/TTD, compound heterozygous XpdTTD/†XPCS, and wt mice.']	(11679, 11901)	['NCBITaxon:10088', 'NCBITaxon:10088', 'PR_EXT:000007164', 'PR_EXT:000007164', 'PR_EXT:000007164', 'SO_EXT:sequence_rescue_process', 'SO_EXT:wild_type_entity_or_quality', 'UBERON_EXT:zone_of_skin_or_skin_of_body', 'UBERON:0000178']
17020410	60	['Insets: images of first-round hair loss.']	(11902, 11942)	['UBERON:0001037']
17020410	61	['(B) Histological analysis of the skin of XpdTTD/TTD, XpdTTD/†XPCS, and wt mice.']	(11944, 12023)	['NCBITaxon:10088', 'PR_EXT:000007164', 'PR_EXT:000007164', 'SO_EXT:wild_type_entity_or_quality', 'UBERON_EXT:zone_of_skin_or_skin_of_body']
17020410	62	['TTD-associated acanthosis (thicker epidermis, indicated by solid vertical line), pronounced granular layer (indicated by arrows), and sebacious gland hyperplasia (indicated by dotted vertical line) were absent in the epidermis of XpdTTD/†XPCS and wt mice.']	(12024, 12279)	['NCBITaxon:10088', 'PR_EXT:000007164', 'SO_EXT:wild_type_entity_or_quality', 'UBERON:0007376', 'UBERON:0001821', 'UBERON:0001821', 'UBERON:0007376']
17020410	63	['Magnification 400×.']	(12280, 12299)	[]
17020410	64	['(C) Cysteine content of hair from wt, XpdTTD/TTD, and XpdTTD/†XPCS mice.']	(12301, 12373)	['CHEBI_SO_EXT:cysteine', 'NCBITaxon:10088', 'PR_EXT:000007164', 'PR_EXT:000007164', 'CHEBI_SO_EXT:cysteine', 'SO_EXT:wild_type_entity_or_quality', 'UBERON:0001037']
17020410	65	['The p-value indicates significant differences between mutants and wt, as well as between XpdTTD/TTD and XpdTTD/†XPCS mice.']	(12374, 12496)	['NCBITaxon:10088', 'PR_EXT:000007164', 'PR_EXT:000007164', 'SO_EXT:sequence_altered_entity', 'SO_EXT:wild_type_entity_or_quality']
17020410	66	['Error bars indicate standard error of the mean (SEM).']	(12497, 12550)	[]
17020410	67	['(D) Hematocrit values from blood of XpdTTD/TTD and XpdTTD/†XPCS mice.']	(12552, 12621)	['NCBITaxon:10088', 'PR_EXT:000007164', 'PR_EXT:000007164', 'UBERON:0000178']
17020410	68	['The p-values indicate the significance of the difference relative to wt.']	(12622, 12694)	['SO_EXT:wild_type_entity_or_quality']
17020410	69	['Error bars indicate SEM.']	(12695, 12719)	[]
17020410	70	['(E) Body weights of developing XpdTTD/TTD and XpdTTD/†XPCS mice after weaning plotted as a percentage of the weight of age-matched control wt and heterozygote (hz) littermates (set at 100%).']	(12721, 12911)	['NCBITaxon:10088', 'PR_EXT:000007164', 'PR_EXT:000007164', 'SO_EXT:wild_type_entity_or_quality', 'UBERON_EXT:body']
17020410	71	['Error bars indicate SEM.']	(12912, 12936)	[]
17020410	72	['Other prominent TTD features in the epidermis, including acanthosis (thickening of the layer of the nucleated cells), hyperkeratosis (prominent thickening of the cornified layer), and pronounced granular layer and sebacious gland hyperplasia (causing greasy appearance of the hair), were absent in the skin of XpdTTD/†XPCS mice, as established by blind microscopic examination of skin sections (Figure 2B).']	(12938, 13344)	['CL:0002242', 'CL:0002242', 'GO:0070268', 'GO:0005634', 'CL_GO_EXT:cell', 'NCBITaxon:10088', 'PR_EXT:000007164', 'UBERON:0007376', 'UBERON:0000119', 'UBERON:0000119', 'UBERON:0000119', 'UBERON:0002027', 'UBERON:0002027', 'UBERON:0001821', 'UBERON:0001821', 'UBERON:0001037', 'UBERON_EXT:zone_of_skin_or_skin_of_body', 'UBERON_EXT:zone_of_skin_or_skin_of_body']
17020410	73	['Furthermore, anaemia and developmental delay present in patients with TTD [24] and in XpdTTD/TTD mice [15] were both partially rescued in compound heterozygous XpdTTD/†XPCS mice (Figure 2D and 2E).']	(13345, 13542)	['NCBITaxon:10088', 'NCBITaxon:10088', 'PR_EXT:000007164', 'PR_EXT:000007164', 'SO_EXT:sequence_rescue_process']
17020410	74	['Rescue of Progeroid Features in TTD Mice by Homozygous Lethal Xpd Alleles\n\nBecause patients with TTD, XPCS, and CS (but not XP) and the corresponding mouse models share similar accelerated progeroid symptoms [12,13,15,23], we next addressed ageing-related parameters in compound heterozygous mice (Figure 3).']	(13544, 13852)	['GO_EXT:fatality_or_lethality', 'GO:0007568', 'NCBITaxon:10088', 'NCBITaxon:10088', 'NCBITaxon:10088', 'PR_EXT:000007164', 'SO_EXT:sequence_rescue_process', 'SO_EXT:0001023']
17020410	75	['Whereas XpdTTD/TTD animals show reduced bone mineral density as an indication of the early onset of osteoporosis before ~14 mo of age [15], tail vertebrae from compound heterozygous XpdTTD/†XPCS mice were comparable to wt even at 20 mo of age (Figure 3B and 3C).']	(13853, 14115)	['CHEBI:46662', 'NCBITaxon:33208', 'NCBITaxon:10088', 'PR_EXT:000007164', 'PR_EXT:000007164', 'SO_EXT:wild_type_entity_or_quality', 'UBERON_EXT:bone_element_or_tissue', 'UBERON:0002415', 'UBERON:0002412']
17020410	76	['Furthermore, whereas XpdTTD/TTD mice developed kyphosis earlier than wt animals (onset ~3 mo versus 12–20 mo), compound heterozygous XpdTTD/†XPCS mice did not (Figure 3B).']	(14116, 14287)	['NCBITaxon:10088', 'NCBITaxon:33208', 'NCBITaxon:10088', 'PR_EXT:000007164', 'PR_EXT:000007164', 'SO_EXT:wild_type_entity_or_quality']
17020410	77	['Overall appearance and body weight curves revealed that TTD-associated age-related premature cachexia and lack of general fitness were fully rescued in compound heterozygous XpdTTD/†XPCS mice (Figure 3A and 3D).']	(14288, 14499)	['NCBITaxon:10088', 'PR_EXT:000007164', 'SO_EXT:sequence_rescue_process', 'UBERON_EXT:body']
17020410	78	['Finally, the life span of compound heterozygotes was extended relative to XpdTTD/TTD mice (Table 2).']	(14500, 14600)	['NCBITaxon:10088', 'PR_EXT:000007164', 'UBERON:0000104', 'UBERON:0000104']
17020410	79	['Figure 3\n\nRescue of TTD-Associated Segmental Progeroid Features in Compound Heterozygous Xpd\u200aTTD/†XPCS Mice\n\n(A) Photographs of 20-mo-old wt, compound heterozygous XpdTTD/†XPCS, and homozygous XpdTTD/TTD mice.']	(14602, 14811)	['NCBITaxon:10088', 'NCBITaxon:10088', 'PR_EXT:000007164', 'PR_EXT:000007164', 'PR_EXT:000007164', 'SO_EXT:sequence_rescue_process', 'SO_EXT:wild_type_entity_or_quality']
17020410	80	['Note the extreme cachexia (lack of subcutaneous fat) in the XpdTTD/TTD mouse and the absence of this phenotype in wt and XpdTTD/†XPCS mice.']	(14812, 14951)	['NCBITaxon:10088', 'NCBITaxon:10088', 'PR_EXT:000007164', 'PR_EXT:000007164', 'SO_EXT:wild_type_entity_or_quality', 'UBERON:0002190', 'UBERON:0002190']
17020410	81	['(B) Radiographs of 20-mo-old male wt, XpdTTD/†XPCS, and XpdTTD/TTD mice.']	(14953, 15025)	['NCBITaxon:10088', 'PR_EXT:000007164', 'PR_EXT:000007164', 'SO_EXT:wild_type_entity_or_quality', 'PATO_UBERON_EXT:male_or_bearer_of_maleness']
17020410	82	['Ageing XpdTTD/TTD mice develop kyphosis (curvature of the spinal column) and reduction of bone mineral density as shown in the 6–8 segment of the tail vertebrae counted from the pelvis (see close-up at right).']	(15026, 15235)	['CHEBI:46662', 'GO:0007568', 'NCBITaxon:10088', 'PR_EXT:000007164', 'UBERON:0001130', 'UBERON:0001130', 'UBERON_EXT:bone_element_or_tissue', 'UBERON:0002415', 'UBERON:0002412', 'UBERON:0002355']
17020410	83	['Note the absence of these features in the XpdTTD\u200a/\u200a†\u200aXPCS mouse.']	(15236, 15300)	['NCBITaxon:10088', 'PR_EXT:000007164']
17020410	84	['(C) Quantification of relative bone mineral density of tail vertebrae from 20-mo-old male wt (n = 3), XpdTTD/†XPCS (n = 4), and XpdTTD/TTD (n = 3) mice.']	(15302, 15454)	['CHEBI:46662', 'NCBITaxon:10088', 'PR_EXT:000007164', 'PR_EXT:000007164', 'SO_EXT:wild_type_entity_or_quality', 'UBERON_EXT:bone_element_or_tissue', 'UBERON:0002415', 'UBERON:0002412', 'PATO_UBERON_EXT:male_or_bearer_of_maleness']
17020410	85	['The p-values indicate the significance of the difference relative to XpdTTD/TTD.']	(15455, 15535)	['PR_EXT:000007164']
17020410	86	['Error bars indicate SEM.']	(15536, 15560)	[]
17020410	87	['(D) Body weight curves as a function of time.']	(15562, 15607)	['UBERON_EXT:body']
17020410	88	['Note that the age-dependent cachexia observed in XpdTTD/TTD mice was rescued in both male and female XpdTTD\u200a/\u200a†XPCS mice.']	(15608, 15729)	['NCBITaxon:10088', 'NCBITaxon:10088', 'PR_EXT:000007164', 'PR_EXT:000007164', 'SO_EXT:sequence_rescue_process', 'PATO_UBERON_EXT:male_or_bearer_of_maleness', 'PATO_UBERON_EXT:female_or_bearer_of_femaleness']
17020410	89	['Significant differences between wt and XpdTTD/TTD but not between wt and XpdTTD/†XPCS mice were observed at 9 and 18 mo of age as indicated by asterisks.']	(15730, 15883)	['NCBITaxon:10088', 'PR_EXT:000007164', 'PR_EXT:000007164', 'SO_EXT:wild_type_entity_or_quality', 'SO_EXT:wild_type_entity_or_quality']
17020410	90	['Error bars indicate SEM.']	(15884, 15908)	[]
17020410	91	['Table 2\n\nPleiotropic Xpd Biallelic Effects in Mice and Cells\n\nTo determine whether the homozygous lethal Xpd†XPCS allele was unique in its ability to ameliorate symptoms associated with the XpdTTD allele, we generated compound heterozygous XpdTTD/†XP mice by crossing the corresponding heterozygous animals.']	(15910, 16217)	['CL_GO_EXT:cell', 'GO_EXT:fatality_or_lethality', 'CL_GO_EXT:cell', 'NCBITaxon:10088', 'NCBITaxon:10088', 'NCBITaxon:33208', 'PR_EXT:000007164', 'PR_EXT:000007164', 'PR_EXT:000007164', 'PR_EXT:000007164', 'SO_EXT:0001023', 'SO_EXT:0001023', 'SO_EXT:0001023']
17020410	92	['Similar to the Xpd\u200a†XPCS allele, the homozygous lethal Xpd\u200a†XP allele rescued cutaneous symptoms including hair loss (except locally during the first round; unpublished data), reduced cysteine content (cysteine index 9.3 ± 0.9 standard deviation [87% of wt], p = 0.01 versus TTD), ageing-associated premature cachexia (males and females were 36.1 ± 6.4 g [93% of wt] and 39.2 ± 3.2 g [116% of wt], respectively), and reduced life span (Table 2).']	(16218, 16663)	['CHEBI_SO_EXT:cysteine', 'CHEBI_SO_EXT:cysteine', 'GO_EXT:fatality_or_lethality', 'GO:0007568', 'PR_EXT:000007164', 'PR_EXT:000007164', 'SO_EXT:0001023', 'SO_EXT:0001023', 'SO_EXT:sequence_rescue_process', 'CHEBI_SO_EXT:cysteine', 'CHEBI_SO_EXT:cysteine', 'SO_EXT:wild_type_entity_or_quality', 'SO_EXT:wild_type_entity_or_quality', 'SO_EXT:wild_type_entity_or_quality', 'UBERON_EXT:zone_of_skin_or_skin_of_body', 'UBERON:0001037', 'PATO_UBERON_EXT:male_or_bearer_of_maleness', 'PATO_UBERON_EXT:female_or_bearer_of_femaleness', 'UBERON:0000104', 'UBERON:0000104']
17020410	93	['Taken together, these data indicate that two independent alleles, which on their own are unable to support viability (Table 1), were nonetheless able to ameliorate TTD-associated phenotypes in vivo (Table 2).']	(16664, 16872)	['SO_EXT:0001023']
17020410	94	['Molecular Mechanisms of Biallelic Effects\n\nWe next turned to UV-based cellular assays including unscheduled DNA synthesis after UV irradiation (UV-UDS), recovery of RNA synthesis after UV irradiation (UV-RRS), and UV survival, which report on the NER subpathways (global genome NER and transcription-coupled NER) and total NER, respectively.']	(16874, 17215)	['CHEBI_EXT:polyatomic_entity_or_group', 'CHEBI_SO_EXT:DNA', 'CHEBI_SO_EXT:RNA', 'CL_GO_EXT:cell', 'GO:0071897', 'GO:0071897', 'GO:0032774', 'GO:0032774', 'GO:0006289', 'GO:0006289', 'GO:0006283', 'GO:0006283', 'GO:0006283', 'GO:0006283', 'GO:0006289', 'CL_GO_EXT:cell', 'SO_EXT:0001023', 'CHEBI_SO_EXT:DNA', 'CHEBI_SO_EXT:RNA', 'SO_EXT:0001026']
17020410	95	['In none of these assays was the response to UV improved in compound heterozygotes relative to TTD homozygotes (Figure 4A–4C).']	(17216, 17341)	['GO_EXT:reaction_or_response']
17020410	96	['However, unlike the in vivo TTD phenotypes described above, in which XpdTTD/TTD and XpdTTD/KO animals were indistinguishable, XpdTTD dosage effects were observed in UV survival, UV-UDS, and UV-RRS, indicating that cellular parameters as measured in fibroblasts here do not always correlate with the phenotype at the level of the intact organism.']	(17342, 17687)	['CL_GO_EXT:cell', 'CL:0000057', 'CL_GO_EXT:cell', 'NCBITaxon:33208', 'NCBITaxon:1', 'PR_EXT:000007164', 'PR_EXT:000007164', 'PR_EXT:000007164']
17020410	97	['XpdTTD/KO hemizygous cells were thus used as the baseline on which to compare the activity of compound heterozygous cells.']	(17688, 17810)	['CL_GO_EXT:cell', 'CL_GO_EXT:cell', 'CL_GO_EXT:cell', 'CL_GO_EXT:cell', 'PR_EXT:000007164']
17020410	98	['Relative to XpdTTD/KO hemizygote cells, UV survival was improved by the homozygous lethal Xpd†XPCS allele in XpdTTD/†XPCS compound heterozygous cells and to a lesser degree by the Xpd†XP allele (Figure 4A).']	(17811, 18017)	['CL_GO_EXT:cell', 'CL_GO_EXT:cell', 'GO_EXT:fatality_or_lethality', 'CL_GO_EXT:cell', 'CL_GO_EXT:cell', 'PR_EXT:000007164', 'PR_EXT:000007164', 'PR_EXT:000007164', 'PR_EXT:000007164', 'SO_EXT:0001023', 'SO_EXT:0001023']
17020410	99	['Because of embryonic and cellular lethality, we were unable to test UV survival associated exclusively with the Xpd†XPCS or Xpd†XP alleles.']	(18018, 18157)	['CL_GO_EXT:cell', 'GO_EXT:fatality_or_lethality', 'CL_GO_EXT:cell', 'PR_EXT:000007164', 'PR_EXT:000007164', 'SO_EXT:0001023', 'UBERON:0000922']
17020410	100	['However, homozygous XPDXP (XPDR683W) and hemizygous XPDXPCS (XPDG602D) human cells are known to be highly sensitive to UV [19,25], as are cells from a homozygous viable XpdXPCS/XPCS (XPDG602D/G602D) mouse model (Figure 4A, dotted line) [23].']	(18158, 18399)	['CL_GO_EXT:cell', 'CL_GO_EXT:cell', 'CL_GO_EXT:cell', 'CL_GO_EXT:cell', 'NCBITaxon:9606', 'NCBITaxon:10088', 'PR_EXT:000007164', 'PR_EXT:000007164', 'PR_EXT:000007164', 'PR_EXT:000007164', 'PR_EXT:000007164', 'PR_EXT:000007164']
17020410	101	['Thus, the survival of XpdTTD/†XPCS (and XpdTTD/†XP) cells likely represents a level of UV resistance that neither mutant allele can impart on its own (Table 2).']	(18400, 18560)	['CL_GO_EXT:cell', 'CL_GO_EXT:cell', 'PR_EXT:000007164', 'PR_EXT:000007164', 'SO_EXT:sequence_altered_entity_or_alteration_process', 'SO_EXT:0001023']
17020410	102	['Significant effects of compound heterozygosity on NER subpathways relative to XpdTTD/KO cells were observed in XpdTTD/†XP cells but only for UV-UDS activity.']	(18561, 18718)	['CL_GO_EXT:cell', 'CL_GO_EXT:cell', 'GO:0006289', 'CL_GO_EXT:cell', 'CL_GO_EXT:cell', 'PR_EXT:000007164', 'PR_EXT:000007164']
17020410	103	['Finally, none of the mutant TFIIH combinations (carrying alterations associated with TTD [XPDR722W], XPCS [XPDG602D], or XP [XPDR683W]) exhibited synergism in an in vitro NER reaction reconstituted with different mutant TFIIH complexes (Figure 4D).']	(18719, 18967)	['GO:0006289', 'GO:0005675', 'GO:0005675', 'GO:0005675', 'PR_EXT:000007164', 'PR_EXT:000007164', 'PR_EXT:000007164', 'SO_EXT:sequence_altered_entity_or_alteration_process', 'SO_EXT:sequence_alteration_entity_or_process', 'SO_EXT:sequence_altered_entity_or_alteration_process']
17020410	104	['Taken together, these data are consistent with interallelic complementation of UV sensitivity in cells but underscore the lack of any correlation between UV-related repair characteristics and TTD progeroid phenotypes in animal models.']	(18968, 19202)	['CL_GO_EXT:cell', 'GO:0006281', 'CL_GO_EXT:cell', 'NCBITaxon:33208', 'SO_EXT:0001023']
17020410	105	['Figure 4\n\nTFIIH Functions and Mechanisms of XPD-Associated Disease Pleiotropy\n\n(A) Cellular survival after UV irradiation.']	(19204, 19326)	['CL_GO_EXT:cell', 'GO:0005675', 'CL_GO_EXT:cell', 'PR_EXT:000007164']
17020410	106	['Rescue of hemizygous XpdTTD/KO survival by Xpd†XPCS and Xpd†XP alleles is illustrated by arrows marked A and B, respectively.']	(19327, 19452)	['PR_EXT:000007164', 'PR_EXT:000007164', 'PR_EXT:000007164', 'SO_EXT:sequence_rescue_process', 'SO_EXT:0001023']
17020410	107	['UV survival of homozygous XpdXPCS/XPCS cells (asterisk) from the normally expressed viable allele (XpdXPCS) is depicted by a dotted line.']	(19453, 19590)	['CL_GO_EXT:cell', 'GO:0010467', 'CL_GO_EXT:cell', 'PR_EXT:000007164', 'PR_EXT:000007164', 'SO_EXT:0001023']
17020410	108	['Survival curves represent an average of four independent experiments; 1–2 cell lines per genotype were included in each experiment.']	(19591, 19722)	['CL_GO_EXT:cell', 'CL_GO_EXT:cell', 'SO_EXT:genotype_or_entity_with_genotype']
17020410	109	['Error bars indicate SEM between experiments.']	(19723, 19767)	[]
17020410	110	['(B) UV-UDS, a measure of global genome repair.']	(19769, 19815)	['GO:0006281', 'SO_EXT:0001026']
17020410	111	['Number of experiments: n = 15 (XpdTTD/TTD), n = 6 (XpdTTD/KO), n = 4 (XpdTTD/†XPCS), n = 2 (XpdTTD/†XP); 1–2 cell lines per genotype were included in each experiment.']	(19816, 19982)	['CL_GO_EXT:cell', 'CL_GO_EXT:cell', 'PR_EXT:000007164', 'PR_EXT:000007164', 'PR_EXT:000007164', 'PR_EXT:000007164', 'SO_EXT:genotype_or_entity_with_genotype']
17020410	112	['The asterisk indicates significant difference with XpdTTD/TTD; crosses indicate significant differences with XpdTTD/KO.']	(19983, 20102)	['PR_EXT:000007164', 'PR_EXT:000007164']
17020410	113	['(C) UV-RRS, a measure of transcription-coupled repair of UV-induced lesions.']	(20104, 20180)	['GO:0006283', 'GO:0006283', 'GO:0006283', 'GO:0006283']
17020410	114	['Number of experiments: n = 7 (XpdTTD/TTD), n = 2 (XpdTTD/KO), n = 4 (XpdTTD/†XPCS), n = 2 (XpdTTD/†XP); 1–2 cell lines per genotype were included in each experiment.']	(20181, 20346)	['CL_GO_EXT:cell', 'CL_GO_EXT:cell', 'PR_EXT:000007164', 'PR_EXT:000007164', 'PR_EXT:000007164', 'PR_EXT:000007164', 'SO_EXT:genotype_or_entity_with_genotype']
17020410	115	['(D) Incision/excision activity of combinations of altered TFIIH complexes in a reconstituted NER reaction.']	(20348, 20454)	['GO:0006289', 'GO:0005675', 'GO:0005675', 'MOP:0000780', 'SO_EXT:sequence_deletion_process', 'SO_EXT:sequence_alteration_process']
17020410	116	['Equal amounts of single or mixed populations of recombinant TFIIHs (containing XPD, XPB, p62, p52, His-p44, Flag-p34, cdk7, cyclin H, Mat1, and p8) were mixed with recombinant XPG, XPF/ERCC1, XPC/hHR23B, RPA, and a radiolabelled synthetic NER substrate.']	(20455, 20708)	['CHEBI_SO_EXT:histidine', 'CHEBI_EXT:radiolabel_process', 'GO_SO_EXT:sequence_rearrangement_process', 'GO_SO_EXT:sequence_rearrangement_process', 'GO:0006289', 'GO:0005675', 'GO:0005662', 'PR_EXT:000007164', 'PR_EXT:000007165', 'PR_EXT:000008317', 'PR_EXT:000008320', 'PR_EXT:000008318', 'PR_EXT:000008319', 'PR_EXT:000005265', 'PR_EXT:000005130', 'PR_EXT:000005130', 'PR_EXT:000010496', 'PR_EXT:000008321', 'PR_EXT:000007167', 'PR_EXT:000007166', 'PR_EXT:000007163', 'PR_EXT:000017494', 'PR_EXT:000013670', 'GO_SO_EXT:sequence_rearrangement_process', 'CHEBI_SO_EXT:histidine', 'GO_SO_EXT:sequence_rearrangement_process']
17020410	117	['The excision products (26–34 nucleotides in length) were visualised at nucleotide resolution on a denaturing polyacrylamide gel as indicated .']	(20709, 20851)	['CHEBI_SO_EXT:nucleotide', 'CHEBI_SO_EXT:nucleotide', 'CHEBI_EXT:polyacrylamide', 'GO_EXT:macromolecule_denaturation', 'SO_EXT:sequence_deletion_process', 'CHEBI_SO_EXT:nucleotide', 'CHEBI_SO_EXT:nucleotide']
17020410	118	['Note the weak activity corresponding to each single and combined TFIIH complex (lanes 3–8) relative to the wt (lane 1) and negative controls (lane 2).']	(20852, 21002)	['GO:0005675', 'GO:0005675', 'SO_EXT:wild_type_entity_or_quality']
17020410	119	['(E) Xpd dose-dependent reduction of TFIIH in homozygous XpdTTD/TTD, hemizygous XpdTTD/KO, and compound heterozygous XpdTTD/†XPCS and XpdTTD/†XP cells by comparative immunofluorescence of the p62 subunit of TFIIH.']	(21004, 21216)	['CL_GO_EXT:cell', 'GO:0005675', 'CL_GO_EXT:cell', 'GO:0005675', 'PR_EXT:000007164', 'PR_EXT:000007164', 'PR_EXT:000007164', 'PR_EXT:000007164', 'PR_EXT:000007164', 'PR_EXT:000008317', 'PR_EXT:000008317', 'PR_EXT:000008317', 'PR_EXT:000008317']
17020410	120	['Roman numerals represent different microscopic slides and Arabic numerals different cell lines labelled as follows: (I) wt cells (1) labelled with 2-μm beads, XpdTTD/TTD cells (2) with 0.79-μm beads, and XpdTTD/KO cells (3) with no beads; (II) wt cells (1) labelled with 0.79-μm beads and XpdTTD/†XPCS cells (4) with no beads; and (III) wt cells (1) labelled with 0.79-μm beads and XpdTTD/†XP cells (5) with no beads.']	(21217, 21634)	['CHEBI_SO_EXT:molecular_label_or_mark_or_tag_process', 'CHEBI_SO_EXT:molecular_label_or_mark_or_tag_process', 'CHEBI_SO_EXT:molecular_label_or_mark_or_tag_process', 'CHEBI_SO_EXT:molecular_label_or_mark_or_tag_process', 'CL_GO_EXT:cell', 'CL_GO_EXT:cell', 'CL_GO_EXT:cell', 'CL_GO_EXT:cell', 'CL_GO_EXT:cell', 'CL_GO_EXT:cell', 'CL_GO_EXT:cell', 'CL_GO_EXT:cell', 'CL_GO_EXT:cell', 'CL_GO_EXT:cell', 'CL_GO_EXT:cell', 'CL_GO_EXT:cell', 'CL_GO_EXT:cell', 'CL_GO_EXT:cell', 'CL_GO_EXT:cell', 'CL_GO_EXT:cell', 'PR_EXT:000007164', 'PR_EXT:000007164', 'PR_EXT:000007164', 'PR_EXT:000007164', 'CHEBI_SO_EXT:molecular_label_or_mark_or_tag_process', 'SO_EXT:wild_type_entity_or_quality', 'CHEBI_SO_EXT:molecular_label_or_mark_or_tag_process', 'SO_EXT:wild_type_entity_or_quality', 'CHEBI_SO_EXT:molecular_label_or_mark_or_tag_process', 'SO_EXT:wild_type_entity_or_quality', 'CHEBI_SO_EXT:molecular_label_or_mark_or_tag_process']
17020410	121	['(F) Quantification of immunofluorescent signal from at least 50 nuclei per cell line and 2–6 experiments per genotype.']	(21636, 21754)	['CL_GO_EXT:cell', 'GO:0005634', 'CL_GO_EXT:cell', 'SO_EXT:genotype_or_entity_with_genotype']
17020410	122	['Bars representing cells analysed on the same microscopic slide are depicted side by side, with wt set at 100%.']	(21755, 21865)	['CL_GO_EXT:cell', 'CL_GO_EXT:cell', 'SO_EXT:wild_type_entity_or_quality']
17020410	123	['The p-value indicates minimum significant difference between wt and the indicated cell lines analysed on the same microscopic slide within one experiment.']	(21866, 22020)	['CL_GO_EXT:cell', 'CL_GO_EXT:cell', 'SO_EXT:wild_type_entity_or_quality']
17020410	124	['Next we asked whether the Xpd†XPCS and Xpd†XP alleles, despite decreased mRNA levels, ameliorated TTD symptoms by increasing overall TFIIH levels in compound heterozygous XpdTTD/\u200a†XPCS and XpdTTD/\u200a†XP cells.']	(22022, 22229)	['CHEBI_SO_EXT:mRNA', 'CL_GO_EXT:cell', 'GO:0005675', 'CL_GO_EXT:cell', 'PR_EXT:000007164', 'PR_EXT:000007164', 'PR_EXT:000007164', 'PR_EXT:000007164', 'SO_EXT:0001023', 'CHEBI_SO_EXT:mRNA']
17020410	125	['Previously, using comparative immunohistochemistry, we and others have shown an up to 70% reduction of TFIIH levels in primary fibroblasts from patients with TTD compared with wt controls due to reduced stability [16,17].']	(22230, 22451)	['CL:0000057', 'GO:0005675', 'SO_EXT:wild_type_entity_or_quality']
17020410	126	['Despite overexpression of mRNA from the XpdTTD allele relative to the wt allele (Figure 1E), TFIIH protein levels were reduced by 50% in primary mouse XpdTTD/TTD fibroblasts (Figure 4E and 4F), thereby mimicking the situation in human patients with TTD.']	(22452, 22705)	['CHEBI_SO_EXT:mRNA', 'CHEBI_PR_EXT:protein', 'CL:0000057', 'GO:0010467', 'GO:0005675', 'NCBITaxon:10088', 'NCBITaxon:9606', 'PR_EXT:000007164', 'CHEBI_PR_EXT:protein', 'PR_EXT:000007164', 'CHEBI_SO_EXT:mRNA', 'SO_EXT:0001023', 'SO_EXT:wild_type_entity_or_quality', 'SO_EXT:0001023']
17020410	127	['In accordance with the gene dosage, a further reduction of up to 70% of the wt level was observed in hemizygous XpdTTD/KO cells.']	(22706, 22834)	['CL_GO_EXT:cell', 'CL_GO_EXT:cell', 'PR_EXT:000007164', 'SO_EXT:0000704', 'SO_EXT:wild_type_entity_or_quality']
17020410	128	['Consistent with low mRNA expression levels, neither the Xpd†XPCS nor the Xpd†XP allele was able to restore TFIIH abundance to wt levels in XpdTTD compound heterozygote cells (Figure 4E and 4F).']	(22835, 23028)	['CHEBI_SO_EXT:mRNA', 'CL_GO_EXT:cell', 'GO:0010467', 'GO:0005675', 'CL_GO_EXT:cell', 'PR_EXT:000007164', 'PR_EXT:000007164', 'PR_EXT:000007164', 'CHEBI_SO_EXT:mRNA', 'SO_EXT:0001023', 'SO_EXT:wild_type_entity_or_quality']
17020410	129	['Thus, the improved UV survival observed in compound heterozygote cells (Figure 4A) and likely the rescue of TTD progeroid symptoms (Figure 3) were not due to normalisation of TFIIH levels, suggesting a qualitative rather than a quantitative effect on these phenotypes in vivo.']	(23029, 23305)	['CL_GO_EXT:cell', 'CL_GO_EXT:cell', 'GO:0005675', 'SO_EXT:sequence_rescue_process']
17020410	130	['In contrast, the level of XPCS mRNA expression did affect the ability of the encoded protein (XPDG602D) to restore the TTD hair phenotype to normal.']	(23307, 23455)	['CHEBI_SO_EXT:mRNA', 'CHEBI_PR_EXT:protein', 'GO:0010467', 'CHEBI_PR_EXT:protein', 'PR_EXT:000007164', 'CHEBI_SO_EXT:mRNA', 'SO_EXT:sequence_coding_function', 'UBERON:0001037']
17020410	131	['Notably, XpdTTD/\u200a†XPCS animals had a partial TTD hair phenotype, correlating with low levels of Xpd†XPCS expression, whereas XpdTTD/XPCS animals had wt hair, correlating with normal expression levels from the viable XpdXPCS allele (Table 2 and unpublished data).']	(23456, 23718)	['GO:0010467', 'GO:0010467', 'NCBITaxon:33208', 'NCBITaxon:33208', 'PR_EXT:000007164', 'PR_EXT:000007164', 'PR_EXT:000007164', 'PR_EXT:000007164', 'SO_EXT:wild_type_entity_or_quality', 'SO_EXT:0001023', 'UBERON:0001037', 'UBERON:0001037']
17020410	132	['Thus, the range of expression levels from these two mutant alleles affected their ability to complement some phenotypes (hair).']	(23719, 23846)	['GO:0010467', 'SO_EXT:sequence_altered_entity_or_alteration_process', 'SO_EXT:0001023', 'UBERON:0001037']
17020410	133	['An overview of the functional relationships between Xpd alleles, phenotypes, and the presumed underlying TFIIH function in mice and cells is presented in Table 2.']	(23847, 24009)	['CL_GO_EXT:cell', 'GO:0005675', 'CL_GO_EXT:cell', 'NCBITaxon:10088', 'PR_EXT:000007164', 'SO_EXT:0001023']
17020410	134	['Discussion\n\nDissection of Biallelic Effects from other Determinants of Phenotype\n\nAlthough phenotypic consequences, referred to here as biallelic effects, resulting from two different mutant alleles in compound heterozygote patients have been postulated, such effects have historically been difficult to distinguish from the influence of environment and genetic background.']	(24011, 24384)	['SO_EXT:0001023', 'SO_EXT:0001023', 'SO_EXT:sequence_altered_entity_or_alteration_process', 'SO_EXT:0001023', 'SO_EXT:0000704']
17020410	135	['We used a genetically defined mammalian model system under controlled environmental conditions to reveal phenotypic effects attributable specifically to combinations of differentially mutated Xpd alleles.']	(24385, 24589)	['NCBITaxon:40674', 'PR_EXT:000007164', 'SO_EXT:0000704', 'SO_EXT:sequence_alteration_process', 'SO_EXT:0001023']
17020410	136	['The observed biallelic effects were of three general types.']	(24591, 24650)	['SO_EXT:0001023']
17020410	137	['In the first, the allele associated in a homozygous state with a phenotype closer to wt singularly determined the phenotypic outcome, a phenomenon widely known in human recessive disease.']	(24651, 24838)	['NCBITaxon:9606', 'SO_EXT:0001023', 'SO_EXT:wild_type_entity_or_quality']
17020410	138	['Because these Xpd alleles functioned at or near wt levels with respect to a particular function, we call these effects “dominant”.']	(24839, 24969)	['PR_EXT:000007164', 'SO_EXT:0001023', 'SO_EXT:wild_type_entity_or_quality']
17020410	139	['Such alleles can also be referred to as “separation of function” alleles, because they allow dissection of the roles of multifunctional proteins in specific phenotypes.']	(24970, 25138)	['CHEBI_PR_EXT:protein', 'CHEBI_PR_EXT:protein', 'SO_EXT:0001023', 'SO_EXT:0001023']
17020410	140	['Secondly, highlighting the potential relevance of current findings to all diploid organisms including humans was the observation that in one compound heterozygous animal, the Xpd allelic relationship could shift from Adominant|arecessive to Arecessive|adominant with respect to different phenotypes in a time-dependent and tissue-specific manner (see below and Table 2).']	(25140, 25510)	['NCBITaxon:1', 'NCBITaxon:9606', 'NCBITaxon:33208', 'PR_EXT:000007164', 'SO_EXT:0001023', 'UBERON:0000479']
17020410	141	['In the third type of biallelic effect, known as interallelic complementation, two mutant alleles produced a phenotype closer to wt than either could alone in a homo- or hemizygous state.']	(25512, 25698)	['SO_EXT:0001023', 'SO_EXT:0001023', 'SO_EXT:sequence_altered_entity_or_alteration_process', 'SO_EXT:0001023', 'SO_EXT:wild_type_entity_or_quality']
17020410	142	['As summarised in Table 2, examples of all types of biallelic effects were observed in a variety of Xpd-associated phenotypes, ranging from brittle hair to segmental progeria.']	(25699, 25873)	['PR_EXT:000007164', 'SO_EXT:0001023', 'UBERON:0001037']
17020410	143	['TFIIH in Transcription and Repair: Mechanisms of XPD Disease Pleiotropy\n\nWe observed differences in the ability of XpdTTD versus homozygous lethal Xpd†XPCS and Xpd†XP alleles to function in two transcription-related phenotypes separated in the organism by both time and space: embryonic lethality and terminal differentiation of enucleating skin and blood cells.']	(25875, 26237)	['CL:0000225', 'CL:0000081', 'CL:0000225', 'CL:0000081', 'GO_EXT:transcription', 'GO:0006281', 'GO_EXT:fatality_or_lethality', 'GO_EXT:transcription', 'GO_EXT:fatality_or_lethality', 'GO:0030154', 'GO:0030154', 'GO:0090601', 'GO:0030154', 'GO:0005675', 'CL_GO_EXT:cell', 'NCBITaxon:1', 'PR_EXT:000007164', 'PR_EXT:000007164', 'PR_EXT:000007164', 'PR_EXT:000007164', 'SO_EXT:0001023', 'UBERON:0000922', 'UBERON_EXT:zone_of_skin_or_skin_of_body', 'UBERON:0000178']
17020410	144	['The preblastocyst-stage homozygous lethality shared by the XpdKO, Xpd†XPCS, and Xpd†XP alleles most likely reflects a defect in basal transcription that is incompatible with life.']	(26238, 26417)	['GO_EXT:fatality_or_lethality', 'GO_EXT:transcription', 'PR_EXT:000007164', 'PR_EXT:000007164', 'PR_EXT:000007164', 'SO_EXT:0001023', 'UBERON:0000358', 'UBERON:0000104']
17020410	145	['In XpdTTD/\u200a†XPCS and XpdTTD/\u200a†XP compound heterozygous mice, embryonic lethality was fully rescued by the XpdTTD allele.']	(26418, 26538)	['GO_EXT:fatality_or_lethality', 'NCBITaxon:10088', 'PR_EXT:000007164', 'PR_EXT:000007164', 'PR_EXT:000007164', 'SO_EXT:sequence_rescue_process', 'SO_EXT:0001023', 'UBERON:0000922']
17020410	146	['Because embryonic lethality was also fully rescued in XpdTTD/KO hemizygous mice, the XpdTTD allele can be considered as wt and thus dominant to each of the homozygous lethal alleles (XpdKO, Xpd†XPCS, and Xpd†XP) with respect to this particular phenotype (Table 2).']	(26539, 26803)	['GO_EXT:fatality_or_lethality', 'GO_EXT:fatality_or_lethality', 'NCBITaxon:10088', 'PR_EXT:000007164', 'PR_EXT:000007164', 'PR_EXT:000007164', 'PR_EXT:000007164', 'PR_EXT:000007164', 'SO_EXT:sequence_rescue_process', 'SO_EXT:0001023', 'SO_EXT:wild_type_entity_or_quality', 'SO_EXT:0001023', 'UBERON:0000922']
17020410	147	['TTD-specific cutaneous and anaemic features, on the other hand, are thought to result from a specific kind of transcriptional insufficiency caused by depletion of unstable TFIIH during the terminal differentiation of skin, hair-shaft, and blood cells [16,24].']	(26805, 27064)	['CL:0002559', 'CL:0002559', 'CL:0002559', 'CL:0000081', 'CL:0000081', 'CL:0002559', 'GO_EXT:transcription', 'GO:0030154', 'GO:0030154', 'GO:0030154', 'GO:0005675', 'CL_GO_EXT:cell', 'UBERON_EXT:zone_of_skin_or_skin_of_body', 'UBERON_EXT:zone_of_skin_or_skin_of_body', 'UBERON:0002074', 'UBERON:0002074', 'UBERON:0002074', 'UBERON:0000178']
17020410	148	['In compound heterozygous mice, both homozygous lethal Xpd†XPCS and Xpd†XP alleles were able to alleviate XpdTTD-specific cutaneous and anaemic features and can thus be defined as dominant over the XpdTTD allele with respect to these phenotypes.']	(27065, 27309)	['GO_EXT:fatality_or_lethality', 'NCBITaxon:10088', 'PR_EXT:000007164', 'PR_EXT:000007164', 'PR_EXT:000007164', 'PR_EXT:000007164', 'SO_EXT:0001023', 'SO_EXT:0001023', 'UBERON_EXT:zone_of_skin_or_skin_of_body']
17020410	149	['We conclude that the defects leading to embryonic lethality and aberrant terminal differentiation of the skin, hair, and blood represent two qualitatively and/or quantitatively different transcriptional deficiencies.']	(27310, 27526)	['GO_EXT:fatality_or_lethality', 'GO_RO_EXT:developmental_differentiation_process', 'GO_EXT:transcription', 'UBERON:0000922', 'UBERON_EXT:zone_of_skin_or_skin_of_body', 'UBERON:0001037', 'UBERON:0000178']
17020410	150	['During early embryonic development, XpdTTD is dominant over the Xpd†XPCS and Xpd†XP alleles, whereas later in the ontogenesis of skin, hair-shaft, and blood cells, the situation is reversed.']	(27527, 27717)	['CL:0002559', 'CL:0002559', 'CL:0002559', 'CL:0000081', 'CL:0000081', 'CL:0002559', 'GO:0009790', 'GO:0009790', 'GO:0043588', 'GO:0048468', 'GO:0043588', 'GO:0048468', 'GO:0043588', 'GO:0048468', 'CL_GO_EXT:cell', 'PR_EXT:000007164', 'PR_EXT:000007164', 'PR_EXT:000007164', 'SO_EXT:0001023', 'UBERON:0019248', 'UBERON:0019248', 'UBERON_EXT:zone_of_skin_or_skin_of_body', 'UBERON:0002074', 'UBERON:0002074', 'UBERON:0002074', 'UBERON:0000178']
17020410	151	['In its role in the repair of UV photolesions, the Xpd†XPCS allele imparted a clear UV survival benefit over a single XpdTTD allele or two XpdXPCS alleles independent of expression levels, which is consistent with interallelic complementation.']	(27719, 27961)	['GO:0006281', 'GO:0010467', 'PR_EXT:000007164', 'PR_EXT:000007164', 'PR_EXT:000007164', 'SO_EXT:0001023', 'SO_EXT:0001023', 'SO_EXT:0001023', 'SO_EXT:0001023']
17020410	152	['However, the observation that no other cellular or biochemical UV-related parameters were improved in XpdTTD/\u200a†XPCS argues against complementation of this repair activity in the rescue of TTD progeroid symptoms in vivo.']	(27962, 28181)	['CHEBI_EXT:biochemical', 'CL_GO_EXT:cell', 'GO:0006281', 'CL_GO_EXT:cell', 'PR_EXT:000007164', 'SO_EXT:sequence_rescue_process']
17020410	153	['Interallelic Complementation and XPD Function\n\nWhat does interallelic complementation tell us about the mechanism of XPD function?']	(28183, 28313)	['PR_EXT:000007164', 'PR_EXT:000007164', 'SO_EXT:0001023', 'SO_EXT:0001023']
17020410	154	['Interallelic complementation is most often observed in multimeric proteins with multiple functional domains.']	(28314, 28422)	['CHEBI_PR_EXT:protein', 'GO:0032991', 'CHEBI_PR_EXT:protein', 'SO_EXT:0001023', 'SO_EXT:0000417']
17020410	155	['Unfortunately, the structure–function relationship between disease-causing mutations and XPD functional domains, including detailed structural information on XPD or even its stoichiometry within TFIIH, remains unknown.']	(28423, 28641)	['GO:0005675', 'PR_EXT:000007164', 'PR_EXT:000007164', 'SO_EXT:sequence_alteration_entity_or_process', 'SO_EXT:0000417']
17020410	156	['However, based on the ability of cell extracts that are defective in two different TFIIH components (XPD and XPB) to complement NER activity in vitro [26], it is likely that TFIIH (or its components) can either multimerise or exchange at least during the NER reaction.']	(28642, 28910)	['CL_GO_EXT:cell', 'GO:0006289', 'GO:0006289', 'CL_GO_EXT:cell', 'GO:0005675', 'GO:0005675', 'PR_EXT:000007164', 'PR_EXT:000007165']
17020410	157	['Furthermore, XPD is known to be a “loosely bound” subunit of TFIIH [27].']	(28911, 28983)	['GO:0005675', 'CHEMINF_GO_EXT:chemical_binding_or_bond_formation', 'PR_EXT:000007164']
17020410	158	['We thus envisage the molecular mechanism of interallelic complementation to involve the exchange of XPD molecules within the TFIIH complex or turnover of TFIIH complexes containing different XPD molecules at the site of DNA damage during the course of the global genome as well as transcription-coupled repair of either UV-induced or endogenous DNA damage.']	(28984, 29340)	['CHEBI_EXT:polyatomic_entity_or_group', 'CHEBI:36357', 'CHEBI:36357', 'CHEBI_SO_EXT:DNA', 'CHEBI_SO_EXT:DNA', 'GO:0006283', 'GO:0006283', 'GO:0006283', 'GO:0006283', 'GO:0006283', 'GO:0006283', 'GO:0006283', 'GO:0005675', 'GO:0005675', 'GO:0005675', 'GO:0005675', 'PR_EXT:000007164', 'PR_EXT:000007164', 'SO_EXT:0001023', 'CHEBI_SO_EXT:DNA', 'SO_EXT:0001026', 'CHEBI_SO_EXT:DNA']
17020410	159	['A Biallelic Paradigm for XPD Disorders\n\nRecently, proteins originating from presumed null alleles were biochemically characterised as inactive in basal transcription [27], providing an explanation as to why these alleles failed to rescue lethality in haploid S. pombe with a null mutation in the XPD homologue rad15 [19].']	(29342, 29663)	['CHEBI_PR_EXT:protein', 'CHEBI_EXT:biochemical', 'GO_EXT:transcription', 'GO_EXT:fatality_or_lethality', 'NCBITaxon:4896', 'NCBITaxon:4896', 'NCBITaxon:4896', 'PR_EXT:000007164', 'CHEBI_PR_EXT:protein', 'PR_EXT:000007164', 'PR_EXT:P26659', 'SO_EXT:0001023', 'SO_EXT:sequence_nullness', 'SO_EXT:0001023', 'SO_EXT:0001023', 'SO_EXT:sequence_rescue_process', 'SO_EXT:sequence_nullness', 'SO_EXT:sequence_alteration_entity_or_process', 'SO_EXT:0000853']
17020410	160	['Our data suggest that certain presumed null alleles, although unable on their own to support basal transcription, may in fact have a substantial impact on disease outcome in compound heterozygous humans, as they do in mouse models.']	(29664, 29895)	['GO_EXT:transcription', 'NCBITaxon:9606', 'NCBITaxon:10088', 'SO_EXT:sequence_nullness', 'SO_EXT:0001023']
17020410	161	['Clinical evidence in support of this hypothesis comes from a number of XP complementation group D patients that do not fit within the framework of the current monoallelic paradigm of XPD disorders (Figure 5).']	(29897, 30105)	['PR_EXT:000007164', 'SO_EXT:0001023']
17020410	162	['In contrast to two hemizygous XPDXPCS patients carrying the XPDG47R- or XPDR666W-encoding alleles who died of the disease before 2 y of age, two compound heterozygous XPDXPCS patients carrying the same XPDG47R- or XPDR666W-encoding alleles in addition to the presumed null XPDL461V+del716−730 both had considerably milder disease symptoms and survived more than ten times longer (A. Lehmann, personal communication) (Figure 5).']	(30106, 30533)	['GO:0016265', 'PR_EXT:000007164', 'PR_EXT:000007164', 'PR_EXT:000007164', 'PR_EXT:000007164', 'PR_EXT:000007164', 'PR_EXT:000007164', 'PR_EXT:000007164', 'SO_EXT:sequence_coding_function', 'SO_EXT:0001023', 'SO_EXT:sequence_coding_function', 'SO_EXT:0001023', 'SO_EXT:sequence_nullness']
17020410	163	['Compound heterozygosity is also associated with the recently reported combination XP and TTD (XPTTD) syndrome [8].']	(30534, 30648)	[]
17020410	164	['Similar to the XpdTTD/†XPCS and XpdTTD/†XP mice described here, both patients with XPTTD described so far had intermediate hair cysteine values.']	(30649, 30793)	['CHEBI_SO_EXT:cysteine', 'NCBITaxon:10088', 'PR_EXT:000007164', 'PR_EXT:000007164', 'CHEBI_SO_EXT:cysteine', 'UBERON:0001037']
17020410	165	['Furthermore, XPTTD patient XP38BR carried a “causative” TTD mutation in one allele and a novel point mutation encoding XPDL485P in the other.']	(30794, 30935)	['PR_EXT:000007164', 'SO_EXT:sequence_alteration_entity_or_process', 'SO_EXT:0001023', 'SO_EXT:point_mutation_entity_or_process', 'SO_EXT:point_mutation_entity_or_process', 'SO_EXT:sequence_coding_function']
17020410	166	['Although the XPDL485P-encoding allele fails to complement viability in the haploid S. pombe rad15 deletion strain and is thus interpretable as a null allele [8], we nonetheless suggest that the combined XPTTD phenotype in this patient involves phenotypic contributions from both alleles.']	(30936, 31223)	['NCBITaxon:4896', 'NCBITaxon:4896', 'NCBITaxon:4896', 'PR_EXT:000007164', 'PR_EXT:P26659', 'SO_EXT:sequence_coding_function', 'SO_EXT:0001023', 'SO_EXT:sequence_deletion_entity_or_process', 'SO_EXT:sequence_nullness', 'SO_EXT:0001023', 'SO_EXT:0001023']
17020410	167	['Taken together, these data suggest a shift to a biallelic paradigm for compound heterozygous patients in XP complementation group D.\n\nFigure 5\n\nGenotype–Phenotype Relationships in XPD Disorders\n\nAccording to the current monoallelic hypothesis, phenotype is determined solely by the causative allele product.']	(31224, 31531)	['PR_EXT:000007164', 'SO_EXT:0001023', 'SO_EXT:genotype_or_entity_with_genotype', 'SO_EXT:0001023', 'SO_EXT:0001023']
17020410	168	['If a second, different allele is present, it is considered a functional null.']	(31532, 31609)	['SO_EXT:0001023', 'SO_EXT:null_sequence_entity']
17020410	169	['There is a lack of any correlation between the site of the XPD mutation and the resulting disorder.']	(31610, 31709)	['PR_EXT:000007164', 'SO_EXT:sequence_alteration_entity_or_process']
17020410	170	['We propose a biallelic hypothesis for compound heterozygotes in which both alleles can contribute to the phenotype.']	(31710, 31825)	['SO_EXT:0001023', 'SO_EXT:0001023']
17020410	171	['Examples of compound heterozygous patients in which a second, presumed null allele is likely to contribute to disease outcome are provided above in comparison to corresponding homo- or hemizygous patients with the same causative allele.']	(31826, 32062)	['SO_EXT:sequence_nullness', 'SO_EXT:0001023', 'SO_EXT:0001023']
17020410	172	['Numbers in the schematic of the protein indicate the helicase domains.']	(32063, 32133)	['CHEBI_PR_EXT:protein', 'GO_EXT:0004386', 'CHEBI_PR_EXT:protein', 'SO_EXT:0000417']
17020410	173	['Potential of Combined Recessive Alleles to Affect Phenotypic Diversity in Mammals\n\nIn humans, the clinical relevance of biallelic effects such as interallelic complementation remains unknown.']	(32135, 32326)	['NCBITaxon:40674', 'NCBITaxon:9606', 'SO_EXT:0001023', 'SO_EXT:0001023', 'SO_EXT:0001023']
17020410	174	['Although interallelic complementation between two endogenous mutant alleles has been described in cells from a compound heterozygous patient with methylmalonic acidaemia, no observable effects on disease outcome were noted in the patient [28].']	(32327, 32570)	['CHEBI:30860', 'CL_GO_EXT:cell', 'CL_GO_EXT:cell', 'SO_EXT:0001023', 'SO_EXT:sequence_altered_entity_or_alteration_process', 'SO_EXT:0001023']
17020410	175	['Thus, to the best of our knowledge, the amelioration of progeroid features observed here is the first in vivo demonstration in compound heterozygous animals of interallelic complementation relevant to a human disease.']	(32571, 32788)	['NCBITaxon:33208', 'NCBITaxon:9606', 'SO_EXT:0001023']
17020410	176	['Keeping in mind that the ~1,200 alleles known to exist for the CTRF gene implicated in the common autosomal recessive disorder cystic fibrosis alone [29] can theoretically result in ~700,000 different allelic combinations, the potential number of allelic combinations of different recessive mutations and single nucleotide polymorphisms genome-wide is currently incalculable.']	(32789, 33164)	['CHEBI_SO_EXT:nucleotide', 'GO:0030849', 'PR_EXT:000001044', 'SO_EXT:0001023', 'SO_EXT:0000704', 'SO_EXT:0001023', 'SO_EXT:0001023', 'SO_EXT:sequence_alteration_entity_or_process', 'SO_EXT:0000694', 'SO_EXT:0000694', 'SO_EXT:0000694', 'SO_EXT:0001026']
17020410	177	['We suggest biallelic effects as a previously underestimated yet important variable in considering genotype–phenotype relationships from autosomal recessive disease to normal phenotypic diversity in mammals.']	(33165, 33371)	['GO:0030849', 'NCBITaxon:40674', 'SO_EXT:0001023', 'SO_EXT:genotype_or_entity_with_genotype']
17020410	178	['Extension of the above concept implies that recessive mutations can enter evolutionary selection in F1 provided that the second allele carries a different recessive alteration.']	(33372, 33548)	['SO_EXT:sequence_alteration_entity_or_process', 'SO_EXT:0001023', 'SO_EXT:sequence_alteration_entity_or_process']
17020410	179	['Finally, our data highlight the potential of clinically relevant alleles previously designated as null, with little or no detectable expression or activity, to nonetheless contribute to phenotype.']	(33549, 33745)	['GO:0010467', 'SO_EXT:0001023', 'SO_EXT:sequence_nullness']
17020410	180	['Materials and Methods\n\nDerivation and analysis of mutant mice.']	(33747, 33809)	['NCBITaxon:10088', 'SO_EXT:sequence_altered_entity_or_alteration_process']
17020410	181	['Generation of XpdTTD (XPDR722W) and XpdTTD/KO mice has been described previously [21,22].']	(33811, 33900)	['NCBITaxon:10088', 'PR_EXT:000007164', 'PR_EXT:000007164', 'PR_EXT:000007164']
17020410	182	['A detailed description of the generation of targeting constructs for Xpd†XPCS and Xpd\u200a†XP alleles carrying mutations encoding the G602D and R683W alterations will be provided upon request.']	(33901, 34089)	['PR_EXT:000007164', 'PR_EXT:000007164', 'SO_EXT:engineered_biological_sequence', 'SO_EXT:0001023', 'SO_EXT:sequence_alteration_entity_or_process', 'SO_EXT:sequence_coding_function', 'SO_EXT:sequence_alteration_entity_or_process']
17020410	183	['Chimeric mice and mouse embryonic fibroblasts were generated according to standard procedures.']	(34090, 34184)	['CL:0000057', 'NCBITaxon:10088', 'NCBITaxon:10088', 'UBERON:0000922']
17020410	184	['Haematoxylin and eosin staining was performed according to standard procedures.']	(34185, 34264)	['CHEBI:51686', 'CHEBI_EXT:eosin']
17020410	185	['Amino acid analysis was conducted as described in [21].']	(34265, 34320)	['CHEBI_SO_EXT:amino_acid', 'CHEBI_SO_EXT:amino_acid', 'CHEBI_SO_EXT:amino_acid', 'CHEBI_SO_EXT:amino_acid']
17020410	186	['Blood values were analysed using Animal Blood Counter Vet (ABX Diagnostix, Montpellier, France).']	(34321, 34417)	['NCBITaxon:33208', 'UBERON:0000178', 'UBERON:0000178']
17020410	187	['Radiographs were taken, and relative bone mineral density was calculated as described in [15].']	(34418, 34512)	['CHEBI:46662', 'UBERON_EXT:bone_element_or_tissue']
17020410	188	['Mice used in this study were in a 129Ola/C57BL6 mixed background unless noted differently.']	(34513, 34603)	['NCBITaxon:10088']
17020410	189	['All experiments involving mice were judged and approved by the national committee for genetic identification of organisms and the animal ethical committee, and were conducted according to national and international guidelines.']	(34604, 34830)	['NCBITaxon:10088', 'NCBITaxon:1', 'NCBITaxon:33208', 'SO_EXT:0000704']
17020410	190	['UV sensitivity, UV-UDS, UV-RRS, and TFIIH incision/excision activity.']	(34832, 34901)	['GO:0005675', 'MOP:0000780', 'SO_EXT:sequence_deletion_process']
17020410	191	['UV survival, UV-UDS, and UV-RRS assays were performed as described previously [21,30].']	(34903, 34989)	[]
17020410	192	['For UV-RRS, average values from the representative experiment containing two wt, three XpdTTD/TTD, two XpdTTD/XPCS, and one XpdTTD/XP cell line are presented.']	(34990, 35148)	['CL_GO_EXT:cell', 'CL_GO_EXT:cell', 'PR_EXT:000007164', 'PR_EXT:000007164', 'PR_EXT:000007164', 'SO_EXT:wild_type_entity_or_quality']
17020410	193	['The ~48% UV-UDS value presented in this study for XpdTTD/TTD cells differs from our previously published data of 25% UV-UDS [21], possibly because of the high variability intrinsic to the assay or routine variations in the cell culture conditions.']	(35149, 35396)	['CL_GO_EXT:cell', 'CL_GO_EXT:cell', 'CL_GO_EXT:cell', 'CL_GO_EXT:cell', 'PR_EXT:000007164']
17020410	194	['For the incision/excision activity assay, recombinant TFIIH was prepared and assayed as described previously [27].']	(35397, 35511)	['GO_SO_EXT:sequence_rearrangement_process', 'GO:0005675', 'MOP:0000780', 'SO_EXT:sequence_deletion_process', 'GO_SO_EXT:sequence_rearrangement_process']
17020410	195	['Comparative immunofluorescence.']	(35513, 35544)	[]
17020410	196	['Latex bead labelling and comparative immunofluorescence analysis of the p62 subunit of the TFIIH was performed as described previously [16,17] using primary mouse embryonic fibroblasts at passages 2–5.']	(35546, 35747)	['CHEBI_SO_EXT:molecular_label_or_mark_or_tag_process', 'CL:0000057', 'GO:0005675', 'NCBITaxon:10088', 'PR_EXT:000008317', 'PR_EXT:000008317', 'PR_EXT:000008317', 'PR_EXT:000008317', 'CHEBI_SO_EXT:molecular_label_or_mark_or_tag_process', 'UBERON:0000922']
17020410	197	['Two or more cell lines per genotype (except for the XpdTTD/†XP cells, in which only one cell line was used in repeated experiments) were used, and experiments were repeated 2–6 times per genotype.']	(35748, 35944)	['CL_GO_EXT:cell', 'CL_GO_EXT:cell', 'CL_GO_EXT:cell', 'CL_GO_EXT:cell', 'CL_GO_EXT:cell', 'CL_GO_EXT:cell', 'PR_EXT:000007164', 'SO_EXT:genotype_or_entity_with_genotype', 'SO_EXT:genotype_or_entity_with_genotype']
17020410	198	['Acknowledgements\n\nWe are very grateful to Steven Bergink, Koos Jaspers, and Bjorn Schumacher for thoughtful discussions and critical reading of the manuscript and to Ruud Koppenol and Tom de Vries for photography.']	(35946, 36159)	[]
17020410	199	['Author contributions.']	(36161, 36182)	[]
17020410	200	['JOA, JJ, JHJH, GTJvdH, and JRM conceived and designed the experiments.']	(36183, 36253)	[]
17020410	201	['JOA, JJ, JdW, FC, DH, MvdV, WT, JH, WJvL, and JRM performed the experiments.']	(36254, 36330)	[]
17020410	202	['JOA, JJ, JdW, FC, DH, MvdV, JH, HBT, WJvL, JME, JHJH, and JRM analyzed the data.']	(36331, 36411)	[]
17020410	203	['JdB and GTJvdH contributed reagents/materials/analysis tools.']	(36412, 36473)	['CHEBI_EXT:33893']
17020410	204	['JOA, JHJH, and JRM wrote the paper.']	(36474, 36509)	[]
17020410	205	['Funding.']	(36511, 36519)	[]
17020410	206	['This research was supported by the Netherlands Organization for Scientific Research (NWO) through the foundation of the Research Institute for Diseases of the Elderly, as well as grants from the National Institutes of Health (1PO1 AG17242–02), National Institute of Environmental Health Sciences (1UO1 ES011044), European Commission (QRTL-1999–02002), and the Dutch Cancer Society (EUR 99–2004).']	(36520, 36915)	[]
17020410	207	['JRM was a fellow of the Damon Runyon Cancer Research Fund (DRG 1677).']	(36916, 36985)	[]
17020410	208	['Abbreviations\n\nbp - base pair\n\nCS - Cockayne syndrome\n\nE[number] - embryonic day [number]\n\nkb - kilobase\n\nNER - nucleotide excision repair\n\nSEM - standard error of the mean\n\nTFIIH - basal transcription/DNA repair factor IIH\n\nTTD - trichothiodystrophy\n\nUV-RRS - recovery of RNA synthesis after ultraviolet irradiation\n\nUV-UDS - unscheduled DNA synthesis after ultraviolet irradiation\n\nwt - wild-type\n\nXP - xeroderma pigmentosum\n\nXPCS - xeroderma pigmentosum combined with Cockayne syndrome\n\nXPTTD - combination xeroderma pigmentosum and trichothiodystrophy\n\nFootnotes\n\nCompeting interests.']	(36987, 37575)	['CHEBI_SO_EXT:base', 'CHEBI_SO_EXT:base', 'CHEBI_SO_EXT:base', 'CHEBI_SO_EXT:nucleotide', 'CHEBI_SO_EXT:DNA', 'CHEBI_SO_EXT:RNA', 'CHEBI_SO_EXT:DNA', 'GO:0006289', 'GO:0006289', 'GO:0006289', 'GO:0006289', 'GO_EXT:transcription', 'GO:0006281', 'GO:0006281', 'GO:0032774', 'GO:0032774', 'GO:0071897', 'GO:0071897', 'GO:0005675', 'GO:0005675', 'GO:0005675', 'GO:0005675', 'GO:0005675', 'GO:0005675', 'GO:0005675', 'GO:0005675', 'GO_EXT:transcription_factor', 'GO_EXT:transcription_factor', 'SO_EXT:0000028', 'SO_EXT:0000028', 'SO_EXT:0000028', 'CHEBI_SO_EXT:base', 'CHEBI_SO_EXT:base', 'CHEBI_SO_EXT:nucleotide', 'SO_EXT:sequence_deletion_process', 'CHEBI_SO_EXT:DNA', 'CHEBI_SO_EXT:RNA', 'CHEBI_SO_EXT:DNA', 'SO_EXT:wild_type_entity_or_quality', 'SO_EXT:wild_type_entity_or_quality', 'SO_EXT:wild_type_entity_or_quality', 'SO_EXT:wild_type_entity_or_quality', 'UBERON:0000922']
17020410	209	['The authors have declared that no competing interests exist.']	(37576, 37636)	[]
17020410	210	['¤a Current address: Institute of Biotechnology, University of Helsinki, Helsinki, Finland\n\n¤b Current address: Department of Molecular and Cell Biology, University of California Berkeley, Berkeley, California, United States of America\n\n¤c Current address: Institute for Biomedical Technology, University of Twente, Bilthoven, Netherlands']	(37638, 37975)	['CHEBI_EXT:polyatomic_entity_or_group', 'CHEBI_GO_EXT:biological_process_or_quality_or_role', 'CL_GO_EXT:cell', 'CHEBI_GO_EXT:biological_process_or_quality_or_role', 'CL_GO_EXT:cell']
